Acalabrutinib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Moderate-Severe Chronic Graft Versus Host Disease
Conditions
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
Trial Timeline
Dec 11, 2020 → Apr 30, 2027
NCT ID
NCT04198922About Acalabrutinib
Acalabrutinib is a phase 2 stage product being developed by AstraZeneca for Recurrent Moderate-Severe Chronic Graft Versus Host Disease. The current trial status is active. This product is registered under clinical trial identifier NCT04198922. Target conditions include Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Moderate-Severe Chronic Graft Versus Host Disease were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06757647 | Phase 2 | Recruiting |
| NCT06651970 | Approved | Recruiting |
| NCT06205498 | Pre-clinical | Active |
| NCT05256641 | Phase 1/2 | Recruiting |
| NCT05557695 | Pre-clinical | Recruiting |
| NCT04660045 | Phase 2 | Withdrawn |
| NCT05038904 | Phase 2 | Completed |
| NCT04198922 | Phase 2 | Active |
| NCT04548648 | Phase 2 | Active |
| NCT04497948 | Phase 1 | Terminated |
| NCT04380688 | Phase 2 | Completed |
| NCT04346199 | Phase 2 | Completed |
| NCT03932331 | Phase 1/2 | Active |
| NCT04008706 | Phase 3 | Completed |
| NCT03968848 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Moderate-Severe Chronic Graft Versus Host Disease